Infants are among the most vulnerable when it comes to RSV—but there's still no vaccination for them. A pediatric vaccine for respiratory syncytial virus (RSV) is proving to be elusive, according to ...

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related RSV ...

Over the course of a two-day meeting, vaccine advisers to the US Food and Drug Administration voted in favor of approval for RSV vaccines for adults over the age of 60. The vaccine candidates, made by ...

As fall approaches, so does respiratory syncytial virus or RSV season. This year, there are more options for those most susceptible to RSV, including a new vaccine and updated RSV vaccine guidance for ...

Far fewer babies went to the hospital struggling to breathe from RSV, a severe respiratory infection, after the debut of a new vaccine and treatment this season, according to an analysis published ...

April 1 (Reuters) - The European Commission approved Pfizer's (PFE.N), opens new tab respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease caused by RSV in adults ...

The FDA approved clesrovimab (Enflonsia) to prevent lower respiratory tract disease from respiratory syncytial virus (RSV) in infants born during or entering their first RSV season, drugmaker Merck ...

The Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus down to age 50 years old, to those who are at higher risk of severe RSV, the company said Friday, ...

TAMPA, Fla. — 'Tis the season... for increased sickness. The winter and holiday season is typically when more people get sick, particularly with respiratory viruses such as the flu, RSV and COVID-19.

Please provide your email address to receive an email when new articles are posted on . Researchers assessed Moderna’s RSV vaccine in solid organ transplant patients. The vaccine was safe and ...

Immune responses to respiratory syncytial virus (RSV) vaccines tended to fall short in older people with weakened immunity, a study found. In 38 immunocompromised persons who received either the ...